Heliospectra (Q1 Initial take): Top-line and Order Intake Beat - Redeye
Bildkälla: Stockfoto

Heliospectra (Q1 Initial take): Top-line and Order Intake Beat - Redeye

Redeye provides its initial take on Heliospectra’s Q1 2026 results. The report is characterised by a solid beat on net sales and order intake, which both significantly exceeded our forecasts. However, this was contrasted by a gross margin that was much weaker than anticipated, leading to a bottom line (EBIT) that only aligned with expectations despite the higher revenue. The underlying commercial activity remains high with several large-scale projects in the pipeline.

Redeye provides its initial take on Heliospectra’s Q1 2026 results. The report is characterised by a solid beat on net sales and order intake, which both significantly exceeded our forecasts. However, this was contrasted by a gross margin that was much weaker than anticipated, leading to a bottom line (EBIT) that only aligned with expectations despite the higher revenue. The underlying commercial activity remains high with several large-scale projects in the pipeline.
Börsvärldens nyhetsbrev